291 related articles for article (PubMed ID: 18094018)
1. Electrocardiographic evidence of ventricular repolarization remodelling during atrial fibrillation.
Tan HL; Smits JP; Loef A; Tanck MW; Hardziyenka M; Campian ME
Europace; 2008 Jan; 10(1):99-104. PubMed ID: 18094018
[TBL] [Abstract][Full Text] [Related]
2. Ibutilide in persistent atrial fibrillation refractory to conventional cardioversion methods.
Naegeli B; Straumann E; Bertel O
Int J Cardiol; 2005 Mar; 99(2):283-7. PubMed ID: 15749188
[TBL] [Abstract][Full Text] [Related]
3. Increase in QT/QTc dispersion after low energy cardioversion of chronic persistent atrial fibrillation.
Boriani G; Valzania C; Biffi M; Corazza I; Camanini C; Martignani C; Bacchi L; Zannoli R; Branzi A
Int J Cardiol; 2004 Jun; 95(2-3):245-50. PubMed ID: 15193827
[TBL] [Abstract][Full Text] [Related]
4. Targeted pharmacological reversal of electrical remodeling after cardioversion--rationale and design of the Flecainide Short-Long (Flec-SL) trial.
Kirchhof P; Fetsch T; Hanrath P; Meinertz T; Steinbeck G; Lehmacher W; Breithardt G
Am Heart J; 2005 Nov; 150(5):899. PubMed ID: 16290956
[TBL] [Abstract][Full Text] [Related]
5. Atrial fibrillation signal organization predicts sinus rhythm maintenance in patients undergoing cardioversion of atrial fibrillation.
Holmqvist F; Stridh M; Waktare JE; Roijer A; Sörnmo L; Platonov PG; Meurling CJ
Europace; 2006 Aug; 8(8):559-65. PubMed ID: 16831838
[TBL] [Abstract][Full Text] [Related]
6. A randomized trial of prophylactic antiarrhythmic agents (amiodarone and sotalol) in patients with atrial fibrillation for whom direct current cardioversion is planned.
Vijayalakshmi K; Whittaker VJ; Sutton A; Campbell P; Wright RA; Hall JA; Harcombe AA; Linker NJ; Stewart MJ; Davies A; de Belder MA
Am Heart J; 2006 Apr; 151(4):863.e1-6. PubMed ID: 16569550
[TBL] [Abstract][Full Text] [Related]
7. [Drug and electrical therapy of supraventricular tachyarrhythmias].
Heisel A; Jung J; Schieffer H
Z Kardiol; 2000; 89 Suppl 3():68-74. PubMed ID: 10810788
[TBL] [Abstract][Full Text] [Related]
8. Temporal changes in atrial refractoriness following DC cardioversion of persistent atrial fibrillation in man.
Spurrell P; Kamalvand K; Higson M; Sulke N
Europace; 2004 May; 6(3):229-35. PubMed ID: 15121076
[TBL] [Abstract][Full Text] [Related]
9. Ibutilide added to propafenone for the conversion of atrial fibrillation and atrial flutter.
Chiladakis JA; Kalogeropoulos A; Patsouras N; Manolis AS
J Am Coll Cardiol; 2004 Aug; 44(4):859-63. PubMed ID: 15312872
[TBL] [Abstract][Full Text] [Related]
10. A randomised, controlled study of rate versus rhythm control in patients with chronic atrial fibrillation and heart failure: (CAFE-II Study).
Shelton RJ; Clark AL; Goode K; Rigby AS; Houghton T; Kaye GC; Cleland JG
Heart; 2009 Jun; 95(11):924-30. PubMed ID: 19282313
[TBL] [Abstract][Full Text] [Related]
11. Atrial fibrillatory rate and sinus rhythm maintenance in patients undergoing cardioversion of persistent atrial fibrillation.
Holmqvist F; Stridh M; Waktare JE; Sörnmo L; Olsson SB; Meurling CJ
Eur Heart J; 2006 Sep; 27(18):2201-7. PubMed ID: 16956916
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of pharmacologic cardioversion of atrial fibrillation by Class I drugs.
Allessie MA; Wijffels MC; Dorland R
J Cardiovasc Electrophysiol; 1998 Aug; 9(8 Suppl):S69-77. PubMed ID: 9727679
[TBL] [Abstract][Full Text] [Related]
13. Enhancing electrical cardioversion and preventing immediate reinitiation of hemodynamically deleterious atrial fibrillation with class III drug pretreatment.
Hayashi M; Tanaka K; Kato T; Morita N; Sato N; Yasutake M; Kobayashi Y; Takano T
J Cardiovasc Electrophysiol; 2005 Jul; 16(7):740-7. PubMed ID: 16050832
[TBL] [Abstract][Full Text] [Related]
14. Impact of sinus rhythm restoration and maintenance on left ventricular function and exercise tolerance in patients with persistent atrial fibrillation.
Kosior DA; Stawicki S; Wozakowska-Kapłon B; Szulc M; Opolski G; Rabczenko D
Kardiol Pol; 2005 Jul; 63(7):36-47; discussion 48-9. PubMed ID: 16136427
[TBL] [Abstract][Full Text] [Related]
15. Impact of matrix metalloproteinase-2 levels on long-term outcome following pharmacological or electrical cardioversion in patients with atrial fibrillation.
Kato K; Fujimaki T; Yoshida T; Oguri M; Yajima K; Hibino T; Murohara T
Europace; 2009 Mar; 11(3):332-7. PubMed ID: 19147485
[TBL] [Abstract][Full Text] [Related]
16. The predictive value of plasma brain natriuretic peptide for the recurrence of atrial fibrillation six months after external cardioversion.
Ari H; Binici S; Ari S; Akkaya M; Koca V; Bozat T; Gürdoğan M
Turk Kardiyol Dern Ars; 2008 Oct; 36(7):456-60. PubMed ID: 19155659
[TBL] [Abstract][Full Text] [Related]
17. Amiodarone after unsuccessful direct-current cardioversion of persistent atrial fibrillation.
Kosior DA; Wozakowska-Kapłon B; Jasik M; Kiliszek M; Rabczenko D; Opolski G
Kardiol Pol; 2005 Dec; 63(6):585-92; discussion 593-4. PubMed ID: 16380855
[TBL] [Abstract][Full Text] [Related]
18. Electrophysiological effects of flecainide and sotalol in the human atrium during persistent atrial fibrillation.
Kirchhof P; Engelen M; Franz MR; Ribbing M; Wasmer K; Breithardt G; Haverkamp W; Eckardt L
Basic Res Cardiol; 2005 Mar; 100(2):112-21. PubMed ID: 15696400
[TBL] [Abstract][Full Text] [Related]
19. Signal-averaged P wave reflects change in atrial electrophysiological substrate afforded by verapamil following cardioversion from atrial fibrillation.
Redfearn DP; Skanes AC; Lane J; Stafford PJ
Pacing Clin Electrophysiol; 2006 Oct; 29(10):1089-95. PubMed ID: 17038141
[TBL] [Abstract][Full Text] [Related]
20. Use of ibutilide in cardioversion of patients with atrial fibrillation or atrial flutter treated with class IC agents.
Hongo RH; Themistoclakis S; Raviele A; Bonso A; Rossillo A; Glatter KA; Yang Y; Scheinman MM
J Am Coll Cardiol; 2004 Aug; 44(4):864-8. PubMed ID: 15312873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
